Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Long-lasting HIV injection is a step closer after second GSK study

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients.

Read More »

Darzalex Dazzles in Multiple Myeloma Late-Stage Trial

Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.

Read More »

Lundbeck Schizophrenia Drug Fails Phase III Study

Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.

Read More »

Ultragenyx Plunges With Phase III Trial Failure

Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Pfizer and Lilly non-opioid drug helps reduce osteoarthritis pain

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

Read More »

AbbVie RA drug succeeds in late-stage trial

Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.

Read More »

Biogen, UCB’s Lupus Treatment Fails Phase II Study

Cambridge, Mass.-based Biogen and Brussels, Belgium-based UCB’s Phase IIb trial of dapirolizumab pegol in lupus failed to hit the primary endpoint, however, the study did show some efficacy and met other secondary endpoints.

Read More »

ESMO 2018: BMS’ Opdivo Shines in RCC Results

An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.

Read More »

Roche scores clinical trial win in slowing aggressive type of breast cancer

An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom